Business Context and Reporting Period
Company: McKesson Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: January 31, 2016
Event: Material Impairments (Item 2.06)
Key Financial Metrics
The filing discloses a specific anticipated financial impact related to a divestiture:
- Anticipated Impairment Charge: Approximately $70 million to $90 million (after-tax).
- Classification: Discontinued operations.
- Timing of Recognition: Primarily upon disposal of the business.
Note: The filing does not provide current period revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
On January 31, 2016, McKesson Corporation entered into a definitive agreement to sell its Brazilian pharmaceutical distribution business. This business was originally acquired through the acquisition of Celesio AG. The transaction represents a material change in the company's asset base and operational footprint.
Outlook, Risks, and Management Commentary
- Closing Conditions: The sale is subject to customary closing conditions.
- Expected Completion: The transaction is expected to be completed during the first quarter of fiscal 2017.
- Financial Impact: Management anticipates the aforementioned impairment charge will be recognized in connection with the sale.
Investor Verification Checklist
- Confirm the final sale price and closing date of the Brazilian pharmaceutical distribution business.
- Verify the exact amount of the impairment charge once the transaction closes.
- Review the impact of the discontinued operations classification on future earnings reports.
- Monitor the first quarter of fiscal 2017 for the recognition of the charge and cash proceeds from the sale.